Catabasis Pharmaceuticals to Present at Upcoming Virtual Investor Conferences
HC Wainwright 22nd Annual
Global Investment Conferenceon Monday, September 14th, at 4:00pm EDT
Cantor Virtual Healthcare Conferenceon Wednesday, September 16th, at 3:20pm EDT
Catabasis will also be participating in the
Live webcasts of the events can be accessed from the investors section of www.catabasis.com. Archived replays will also be available for 30 days following the event.
About Edasalonexent (CAT-1004)
Edasalonexent (CAT-1004) is an investigational oral small molecule designed to inhibit NF-kB that is being developed as a potential foundational therapy for all patients affected by DMD, regardless of their underlying mutation. In DMD the loss of dystrophin leads to chronic activation of NF-kB, which is a key driver of skeletal and cardiac muscle disease progression. The ongoing global Phase 3 PolarisDMD trial is evaluating the efficacy and safety of edasalonexent for registration purposes. Edasalonexent is also being evaluated in the GalaxyDMD open-label extension trial. In the MoveDMD Phase 2 trial and open-label extension, the Company observed that edasalonexent preserved muscle function and substantially slowed disease progression compared to rates of change in a control period, and significantly improved biomarkers of muscle health and inflammation. The FDA has granted orphan drug, fast track, and rare pediatric disease designations and the